Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Current assets | ||||||||||
Cash, cash equivalents and short term investments | 4.26%96.54M | 9.67%108.27M | 24.51%126.87M | 24.51%126.87M | -22.36%80.02M | -36.90%92.6M | -36.02%98.73M | -32.25%101.9M | -32.25%101.9M | 62.52%103.06M |
-Cash and cash equivalents | -28.57%8.93M | 29.97%10.47M | 338.99%70.4M | 338.99%70.4M | -82.43%5.93M | -91.48%12.5M | -94.78%8.06M | -89.34%16.04M | -89.34%16.04M | -46.79%33.74M |
-Short-term investments | 9.38%87.61M | 7.86%97.8M | -34.22%56.48M | -34.22%56.48M | 6.89%74.09M | --80.09M | --90.67M | --85.86M | --85.86M | --69.32M |
Other current assets | -38.23%2.15M | -51.34%1.91M | -40.98%1.78M | -40.98%1.78M | -11.20%2.19M | 305.47%3.49M | 200.00%3.92M | 77.92%3.01M | 77.92%3.01M | 169.29%2.46M |
Total current assets | 2.72%98.69M | 7.34%110.18M | 22.63%128.65M | 22.63%128.65M | -22.10%82.21M | -34.90%96.09M | -34.04%102.65M | -31.03%104.91M | -31.03%104.91M | 64.04%105.53M |
Non current assets | ||||||||||
Net PPE | -24.14%1.71M | -10.48%1.85M | -9.58%1.98M | -9.58%1.98M | -8.83%2.12M | -8.35%2.25M | 868.08%2.06M | 1,205.36%2.19M | 1,205.36%2.19M | 1,096.39%2.32M |
-Gross PPE | -24.14%1.71M | -10.48%1.85M | -7.69%2.09M | -7.69%2.09M | -8.83%2.12M | -8.35%2.25M | 868.08%2.06M | 988.46%2.26M | 988.46%2.26M | 1,096.39%2.32M |
-Accumulated depreciation | ---- | ---- | -50.70%-107K | -50.70%-107K | ---- | ---- | ---- | -77.50%-71K | -77.50%-71K | ---- |
Investments and advances | 161.78%8.78M | 17.29%9.55M | -98.40%263K | -98.40%263K | -94.00%1.57M | --3.35M | --8.14M | --16.47M | --16.47M | --26.21M |
Other non current assets | 510.34%2.83M | 1,141.89%1.84M | 1,141.89%1.84M | 1,141.89%1.84M | 1,141.89%1.84M | 213.51%464K | 0.00%148K | 0.00%148K | 0.00%148K | -97.04%148K |
Total non current assets | 119.51%13.31M | 27.83%13.24M | -78.29%4.08M | -78.29%4.08M | -80.73%5.53M | 133.09%6.07M | 2,768.14%10.35M | 5,852.85%18.81M | 5,852.85%18.81M | 447.10%28.68M |
Total assets | 9.65%112.01M | 9.22%123.41M | 7.29%132.74M | 7.29%132.74M | -34.62%87.74M | -31.99%102.15M | -27.56%113M | -18.83%123.72M | -18.83%123.72M | 92.90%134.21M |
Liabilities | ||||||||||
Current liabilities | ||||||||||
Payables | -12.36%3.15M | -10.53%2.18M | 49.92%4.9M | 49.92%4.9M | 18.73%3.5M | 26.47%3.59M | 119.10%2.43M | 188.78%3.27M | 188.78%3.27M | 89.27%2.95M |
-accounts payable | -12.36%3.15M | -10.53%2.18M | 49.92%4.9M | 49.92%4.9M | 18.73%3.5M | 26.47%3.59M | 119.10%2.43M | 188.78%3.27M | 188.78%3.27M | 89.27%2.95M |
Current accrued expenses | 106.67%2.88M | 0.86%2.58M | 358.58%2.33M | 358.58%2.33M | 80.82%2.03M | 30.16%1.39M | 111.85%2.56M | -58.51%507K | -58.51%507K | 46.73%1.12M |
Current debt and capital lease obligation | 11.34%599K | 11.24%584K | 4.99%568K | 4.99%568K | 73.04%552K | 222.16%538K | 368.75%525K | 400.93%541K | 400.93%541K | 198.13%319K |
-Current capital lease obligation | 11.34%599K | 11.24%584K | 4.99%568K | 4.99%568K | 73.04%552K | 222.16%538K | 368.75%525K | 400.93%541K | 400.93%541K | 198.13%319K |
Current liabilities | 32.47%10.61M | 11.06%7.99M | 84.73%9.61M | 84.73%9.61M | 58.58%6.96M | 26.85%8.01M | 196.21%7.2M | 111.21%5.2M | 111.21%5.2M | 52.43%4.39M |
Non current liabilities | ||||||||||
Long term debt and capital lease obligation | -32.51%1.33M | -17.36%1.5M | -14.30%1.66M | -14.30%1.66M | -11.48%1.82M | -10.06%1.98M | 3,602.04%1.81M | 2,321.25%1.94M | 2,321.25%1.94M | -85.72%2.06M |
-Long term capital lease obligation | -32.51%1.33M | -17.36%1.5M | -14.30%1.66M | -14.30%1.66M | -11.48%1.82M | -10.06%1.98M | 3,602.04%1.81M | 2,321.25%1.94M | 2,321.25%1.94M | 1,820.56%2.06M |
Derivative product liabilities | 8.66%477K | 13.38%483K | 13.59%468K | 13.59%468K | 1,712.08%8.1M | 1.15%439K | 1.43%426K | 1.23%412K | 1.23%412K | 13.16%447K |
Total non current liabilities | -25.02%1.81M | -11.52%1.98M | -9.41%2.13M | -9.41%2.13M | 296.44%9.92M | -8.21%2.41M | 377.61%2.24M | 382.34%2.35M | 382.34%2.35M | -83.08%2.5M |
Total liabilities | 19.15%12.42M | 5.70%9.97M | 55.44%11.73M | 55.44%11.73M | 144.97%16.88M | 16.54%10.42M | 225.57%9.44M | 155.99%7.55M | 155.99%7.55M | -61.00%6.89M |
Shareholders'equity | ||||||||||
Share capital | 52.50%61K | 48.65%55K | 43.24%53K | 43.24%53K | 8.11%40K | 8.11%40K | 0.00%37K | 8.82%37K | 8.82%37K | 131.25%37K |
-common stock | 52.50%61K | 48.65%55K | 43.24%53K | 43.24%53K | 8.11%40K | 8.11%40K | 0.00%37K | 8.82%37K | 8.82%37K | 131.25%37K |
-Preferred stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Retained earnings | -24.58%-360.55M | -25.16%-344.82M | -26.23%-329.44M | -26.23%-329.44M | -23.45%-306.47M | -24.44%-289.42M | -25.79%-275.51M | -24.76%-260.99M | -24.76%-260.99M | -24.27%-248.26M |
Paid-in capital | 20.69%460.02M | 20.72%457.92M | 19.34%450.47M | 19.34%450.47M | 0.45%377.37M | 1.96%381.15M | 1.95%379.32M | 5.25%377.47M | 5.25%377.47M | 49.27%375.67M |
Gains losses not affecting retained earnings | 233.33%64K | 201.76%289K | 77.49%-79K | 77.49%-79K | 40.91%-78K | ---48K | ---284K | ---351K | ---351K | ---132K |
Total stockholders'equity | 8.57%99.59M | 9.54%113.44M | 4.16%121M | 4.16%121M | -44.34%70.86M | -35.07%91.73M | -32.35%103.56M | -22.28%116.17M | -22.28%116.17M | 145.28%127.32M |
Total equity | 8.57%99.59M | 9.54%113.44M | 4.16%121M | 4.16%121M | -44.34%70.86M | -35.07%91.73M | -32.35%103.56M | -22.28%116.17M | -22.28%116.17M | 145.28%127.32M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |